妊娠期血栓性微血管病:sFlt1/PlGF比值的作用
本文报道一例携带致病性C3变异的孕妇在28+5周发生补体介导的血栓性微血管病(C-TMA)并需血液透析,低sFlt1/PlGF比值排除子痫前期,经依库珠单抗治疗并监测药物浓度后安全推迟至34+3周分娩,母婴健康;
要点
- 妊娠期C-TMA需与子痫前期鉴别,sFlt1/PlGF比值低有助于排除子痫前期。
- 依库珠单抗治疗C-TMA时进行药物浓度监测可优化剂量。
- C-TMA孕妇经积极治疗可延长孕周并改善母婴结局。
核心结论
- C-TMA孕妇经依库珠单抗治疗和药物监测可成功妊娠并分娩健康新生儿。
- 低sFlt1/PlGF比值可能有助于排除子痫前期并指导治疗。
研究设计与样本
- 病例报告:一例妊娠28+5周发生C-TMA并需血液透析的孕妇。
- 队列报告:11例TMA合并妊娠患者测量sFlt1/PlGF比值。
主要发现
- 病例中低sFlt1/PlGF比值排除子痫前期,依库珠单抗治疗并监测药物浓度,分娩推迟至34+3周,新生儿健康。
关键数值与推荐
- 低sFlt1/PlGF比值用于排除子痫前期,具体阈值原文未报告。
- 依库珠单抗治疗期间进行治疗药物监测以优化剂量。
临床怎么用
- 妊娠期怀疑TMA时应检测sFlt1/PlGF比值以鉴别子痫前期。
- 确诊C-TMA后应尽早启用补体抑制剂并监测药物浓度。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Thrombotic microangiopathies (TMAs) are severe endotheliopathies that can arise in pregnancy and require early recognition. Complement-mediated (C-)TMA should be differentiated from other endotheliopathies of pregnancy because the treatment differs. Here, we report a case of a pregnant woman with acute kidney injury requiring hemodialysis due to C-TMA on the background of a pathogenic C3 variant at 28+5 weeks of gestation. The low soluble Fms-like tyrosine kinase-1 to placental growth factor (sFlt1/PlGF) ratio excluded pre-eclampsia. Eculizumab was started, and therapeutic drug monitoring was applied for optimal dosing. Despite prolonged hemodialysis, fetal well-being was preserved, and delivery was safely postponed till 34+3 weeks of gestation, resulting in a healthy neonate. We also separately report on sFlt1/PlGF ratios measured in a cohort of 11 patients with TMA and coexisting pregnancy. Ten of 11 patients (91%) had low sFlt1/PlGF ratios, excluding pre-eclampsia. Thus, successful pregnancy in women with C-TMA can occur, and sFlt1/PlGF ratios may aid in clarifying the diagnosis and appropriate treatment.
引用
- van Doorn DPC, Al-Nasiry S, Spaanderman MEA, et al. Thrombotic Microangiopathy During Pregnancy: Role of Soluble Fms-like Tyrosine Kinase-1-Placental Growth Factor Ratios. Am J Kidney Dis. 2025. PMID: 41352724. doi:10.1053/j.ajkd.2025.09.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。